Titlebook: Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Anal; Selected Papers from Jianchang Lin,Bu

抗体

Assessing Benefit and Consistency of Treatment Effect Under a Discrete Random Effects Model in Multi effect due to regional differences. Lan and and Pinheiro (2012) proposed a discrete random effects model (DREM) to account the treatment effects heterogeneity among regions. However, the benefit of the overall drug effect and the consistency of the treatment effect in each region are two major issu

facetious

Design and Analysis of Multiregional Clinical Trials in Evaluation of Medical Devices: A Two-Componef interest is assumed consistent among US and OUS regions. In this paper, we discuss the situations where the treatment effect might vary among US and OUS regions, and propose a two-component Bayesian approach for targeted decision making. In this approach, anticipated treatment difference among US

indignant

扫兴

Explained Variation for Correlated Survival Data Under the Proportional Hazards Mixed-Effects Model explained by one or more other variables. We develop such measures for correlated survival data, under the proportional hazards mixed-effects model (PHMM). Since different approaches have been studied in the literature outside the classical linear regression model, we investigate four sample-based

Acumen

Design and Analysis of Multiregional Clinical Trials in Evaluation of Medical Devices: A Two-Compone OUS regions, and propose a two-component Bayesian approach for targeted decision making. In this approach, anticipated treatment difference among US and OUS regions is formally taken into account by design, hopefully leading to increased transparency and predictability of targeted decision making.

Hallowed

Conference proceedings 2016ical applications in business and finance to applications in clinical trials and biomarker analysis.  Each papers was peer-reviewed by at least two referees and also by an editor.  The conference was attended by over 400 participants from academia, industry, and government agencies around the world, including from North America, Asia, and Europe..

savage

BOON

https://doi.org/10.1007/978-3-319-42568-9Bayesian statistics; personalized medicine; survival analysis; adaptive designs; statistical genetics; no

Minutes

Some Misconceptions on the Use of Composite EndpointsComposite endpoint has been used frequently as a primary endpoint in clinical trials. However, there are some misconceptions on the use of composite endpoints. This paper identifies these misconceptions and discusses how to avoid them.

dithiolethione

Jianchang Lin,Bushi Wang,Ray LiuFocuses on statistical applications from clinical trials, biomarker analysis, and personalized medicine to applications in finance and business analytics.A unique selection of papers from broad and mu